


FIG. 1


25
20
15
10
5
0
IMMUNOREACTIVITY (MICE INDEX)
CONTROL
THYMALFASIN
+6.62%
*
*
*
BCL-2
Fas L
Fas R
TNF R1

FIG. 2


MTT ABSORBANCE (540nm)
0.2
0.18
0.16
0.14
0.12
0.1
0.08
0.06
0.04
0.02
0
-26.6
NO THY
THY

FIG. 3


CONTROL
CHRONIC
ACUTE
0
-5
-10
-15
-20
-25
-30
-35
% REDUCTION IN VIABILITY (ATP Lum)
-0%
-8.06%
-33.85%

FIG. 4A


CONTROL
CHRONIC
ACUTE
10
0
-10
-20
-30
-40
-50
-60
-70
% REDUCTION IN VIABILITY (ATP Lum)
0%
+1.59%
-61.48%

FIG. 4B


TUMOR DIAMETER (mm)
0
2
4
6
8
10
12
0
5
10
15
20
25
DAYS POST-INOCULATION
BEHAVIORAL DISTURBANCES
HEMORRHAGE
HERNIATION

FIG. 5


TUMOR BURDEN
5
4
3
2
1
0
14 DAYS POST-TREATMENT
P<0.001
CONTROL
BCNU
BCNU+THY

FIG. 6




FIG. 7